Latest Trials

EudraCT Number: 2004-004722-27 Sponsor Protocol Number: ICT-BEM-2004-01 Start Date: 2005-05-12
Sponsor Name: Instituto Científico y Tecnológico de Navarra, S.A.
Full Title: Randomised, open, multicenter, sequential trial assessing the safety and efficacy of bemiparin on the response to the treatment in patients diagnosed with localized small cell carcinoma of the lung.
Medical condition: Small cell carcionoma of the lung medDRA CLASSIFICATION CODE: PT 10041071
Disease: Version SOC Term Classification Code Term Level
4.0 10041071 PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: ES (Prematurely Ended)
Trial results: (No results available)
EudraCT Number: 2004-000980-93 Sponsor Protocol Number: I-ICRNS-003-VLPNX-01 Start Date: 2005-05-12
Sponsor Name: CRINOS S.P.A.
Full Title: A randomised, double blind, multicentre Italian study, to assess the efficacy and tolerability of octatropine methilbromide in combination with diazepam(Valpinax) compared versus placebo in the tre...
Medical condition: vascular disease at thrombotic risk
Disease: Version SOC Term Classification Code Term Level
6.1 10023003 PT
Population Age: Adults Gender: Male, Female
Trial protocol: IT (Completed)
Trial results: (No results available)
EudraCT Number: 2005-001459-39 Sponsor Protocol Number: DIV-01/04 Start Date: 2005-05-12
Sponsor Name: SOFAR SPA
Full Title: Efficacy of mesalazine in the long term prevention of diverticulitis relapses. Randomised study, double blind, controlled vs placebo.
Medical condition: Prevention of diverticulitis relapses
Disease: Version SOC Term Classification Code Term Level
14.1 100000004862 10013540 Diverticulitis intestinal LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: IT (Completed)
Trial results: (No results available)
EudraCT Number: 2004-000166-13 Sponsor Protocol Number: 24-02 Start Date: 2005-05-12
Sponsor Name: International Breast Cancer Study Group (IBCSG)
Full Title: A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer.
Medical condition: Histologically proven, resected breast cancer with ER and/or PgR positive tumors
Disease: Version SOC Term Classification Code Term Level
7.0 10057654 LLT
Population Age: Adults Gender: Female
Trial protocol: DK (Ongoing) SE (Ongoing) DE (Completed) ES (Ongoing) IE (Ongoing) HU (Ongoing)
Trial results: (No results available)
EudraCT Number: 2005-000171-18 Sponsor Protocol Number: 3066A2-214-WW Start Date: 2005-05-12
Sponsor Name: Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
Full Title: A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Stud...
Medical condition: Multiple Sclerosis (Relapsing-remitting MS and Secondary progressive MS with relapses)
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Male, Female
Trial protocol: FI (Completed)
Trial results: (No results available)
EudraCT Number: 2005-000360-45 Sponsor Protocol Number: A1481222 Start Date: 2005-05-12
Sponsor Name: PFIZER
Full Title: A MULTICENTER, PARALLEL GROUP FLEXIBLE DOSE STUDY WITH A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED PHASE AND AN OPEN-LABEL PHASE TO EVALUATE THE QUALITY OF ERECTIONS IN MEN WITH ERECTILE DYSFU...
Medical condition: Erectil Dysfunction
Disease: Version SOC Term Classification Code Term Level
6.1 10057672 PT
Population Age: Adults Gender: Male
Trial protocol: IT (Completed) DE (Completed)
Trial results: View results
EudraCT Number: 2004-002399-40 Sponsor Protocol Number: Start Date: 2005-05-11
Sponsor Name: Rigshospitalet
Full Title: Carboplatin + paclitaxel vs carboplatin + stealth liposomal doxorubicin. A randomised multicentre trial.
Medical condition: Recurrent ovarian cancer Cytologic / histologic diagnosis of stage IC-IV ovarian cancer
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Female
Trial protocol: DK (Prematurely Ended)
Trial results: (No results available)
EudraCT Number: 2005-001019-23 Sponsor Protocol Number: 04-TH01-01 Start Date: 2005-05-11
Sponsor Name: BioInvent International AB
Full Title: A double blind, phase I/II, randomized, single and repeat dose, dose escalation study of the antibody BI-201 directed against Tat, given IV, versus Placebo in asymptomatic HIV-1 patients.
Medical condition: HIV-1 (asymptomatic patients)
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Male, Female
Trial protocol: GB (Completed)
Trial results: (No results available)
EudraCT Number: 2004-004577-28 Sponsor Protocol Number: MCB 0402 INT Start Date: 2005-05-10
Sponsor Name: LEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S )
Full Title: Different treatment regimens of calcipotriol cream and combination (calcipotiol/betamethasone dipropionate) ointment in psoriasis vulgaris
Medical condition: Psoriasis vulgaris of the trunk and/or limbs with at least 10% involvement of arms and/or 10% of legs and/or 10% of trunk
Disease: Version SOC Term Classification Code Term Level
7.0 10050576 LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: GB (Completed) DE (Completed) BE (Completed) ES (Completed)
Trial results: View results
EudraCT Number: 2004-003742-18 Sponsor Protocol Number: 1208.10 Start Date: 2005-05-10
Sponsor Name: Boehringer Ingelheim Finland Ky
Full Title: A ten-week, randomized, double-blind study evaluating the efficacy of Duloxetine 60 mg once daily versus placebo in outpatients with major depressive disorder and pain (EU-Pain enriched study)
Medical condition: Depressed patients (according to DSM-IV criteria) experiencing painful physical symptoms
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: FI (Completed) SK (Completed) CZ (Completed) DE (Completed)
Trial results: View results

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe